नैनोमेडिसिन और नैनोटेक्नोलॉजी जर्नल

अमूर्त

Preoperative Cancer Nano medicine: Neoadjuvant Chemotherapy, Radiation, Immunotherapy, And Phototherapy Made Possible by Nanotechnology

Zhang Shang*

Malignant solid tumours are still mostly treated with surgical resection. However, in the past 10 years, there has been an increase in interest in the use of neo-adjuvant therapies, such as chemotherapy, radiation, phototherapy, and immunotherapy, either alone or in combination, as a preoperative intervention regimen [1].

The survival rates of long-term neoadjuvant treatment and adjuvant therapy have not been significantly different in early randomised, controlled studies in several tumour situations. However, due to the clear down staging of primary tumours to define the surgical margin, the ability to tailor systemic therapy response as a clinical tool to optimise subsequent therapeutic regimens, and the reduction in the need for surgery with its potential for increased morbidity, neoadjuvant treatments are being used more frequently in clinical practise. Neo-adjuvant treatment for preoperative therapies now faces obstacles that can be addressed with a new strategy thanks to the recent advancements in nanotechnology-based Nano medicine and associated medical technologies [2]. This study highlights the potential use of nanomedicine as neoadjuvant therapy in preclinical and clinical settings for tumour management in addition to summarising how crucial a role Nanomedicine plays in a variety of neoadjuvant therapeutic methods [3].